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ABSTRACT 
OBJECTIVE: The aim of the study is to compare the live birth rates between 1,500 I.U. of Human chori-
onic gonadotropin at the time of Gonadotropin-releasing hormone agonist trigger day or 35-36 h later on 
the oocyte pick-up day, without affecting the risk of significant ovarian hyperstimulation syndrome de-
velopment in high-risk patients with peak E2 level <4,000 pg/mL 
STUDY DESIGN: This single-center prospective cohort study encompassed the period from March 
2016 to March 2018 year. A total of 216 patients entered for final analysis, underwent a flexible antag-
onist protocol, intracytoplasmic sperm injection, and embryo transfer on the 3rd or 5th day in autologous 
cycles. Patients were randomized in one of two groups: Group A- Dual trigger group - 1,500 IU of Human 
chorionic gonadotropin at the time of Gonadotropin-releasing hormone agonist trigger day and Group B- 
1,500 IU of Human chorionic gonadotropin 35-36 h later, on the oocyte pick-up day. To compare the two 
groups, we used nonparametric and parametric statistical tests. Significant differences were considered 
all values of p<0.05. 
RESULTS: There is no significant difference between the two (A vs B) groups according to the average 
number of retrieved oocytes (13.08 vs 14.41 p=0.08), M II oocytes (10.5 vs 10.95 p=0.46), GV (1.24 vs 
1.52 p=0.09, the fertility rate (68.46% vs 64.04% p=0.07). The dual trigger group (A) had a significantly 
higher live birth rate (62.29% vs 42.37% p<0.05) compared with the Gonadotropin-releasing hormone-
a trigger group (B). There were no cases of moderate or severe ovarian hyperstimulation syndrome in 
both groups. 
CONCLUSION: Our study shows that in hyper responders where the E2 peak is <4,000 pg/mL, the two 
approaches to the final oocyte maturation trigger have a correct outcome of the results, both in terms of 
the results from the in vitro fertilization and the low risk of ovarian hyperstimulation syndrome appearance. 
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moderately and severe hyperstimulation is generally 3.1 to 
8%, but in high-risk responders, women with young age, low 
body mass index (BMI) and polycystic ovarian syndrome 
(PCOS), the percentage is over 20% accompanied by high 
morbidity and even patient mortality in some cases (1,2). The 
introduction of the antagonist protocol with agonist (GnRH-a) 
as a trigger for oocyte maturation has dramatically reduced 
this incidence (3). The advantage of this type of trigger 
(GnRH agonist) eliminates the risk for OHSS because of its 
short half-life in IVF cycles, but there is controversy regard-
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Оvarian hyperstimulation syndrome (OHSS) is a serious 
iatrogenic complication as a result of a response to go-
nadotropin and hCG application as a trigger. The incidence of 
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ing the pregnancy rates (because of the luteal phase defect). 
Over the years, the agonist (GnRH-a) trigger protocol has 
been supplemented with аpplication of intensive steroid luteal 
support (4) raising the results of in vitro fertilization and re-
ducing the incidence of OHSS up to 0.72% in some studies 
(5). On the other hand, the results of some studies show con-
flicting results despite the intense luteal support. The use of 
drugs for intensive luteal support gives better results such as 
higher pregnancy rates but only in a sub-group of patients 
(estradiol peak ≥4,000 pg/mL), not in all of the patients trig-
gered with GnRH agonist. The hypothesis is that patients with 
high levels of estradiol peak ≥4,000 pg/mL have higher serum 
levels of luteinizing hormone (LH) causing solid restitution of 
luteal function (6). On the other hand, the second group re-
quires LH support, so adding a low bolus dose of LH or hCG  
(which has the same LH effect) on the day of follicular aspi-
ration results in optimal steroid secretion (7). To improve the 
results of IVF, an alternative approach is adding a small bolus 
dose of hCG combined with GnRH-a, which improves oocyte 
maturation and provides more sustained support for the corpus 
luteum (8). Even though the bolus dose of hCG is very low, it 
still increases the risk of OHSS occurrence, however, cases of 
moderate and severe OHSS occurrence have only been re-
ported in studies where the dual trigger was administered at 
peak estradiol ≥4,000 pg/mL or patients with a large number 
of aspirated oocytes (9). Therefore, it is essential to select pa-
tients who will benefit from dual triggering. The aim of this 
study is to compare the quality and quantity of the oocytes, 
pregnancy outcomes, live birth, and safety of OHSS occur-
rence on fresh transfer in hyper responders with a peak of 
estradiol <4,000 pg/mL and restitution of luteal phase when 
added a small bolus dose of hCG.  
Material and method  
This is a single-center prospective cohort study encom-
passed the period from March 2016 to March 2018 year real-
ized on patients underwent in vitro fertilization at In Vitro 
Fertilisation Centre, First Private General Hospital Re-
Medika, Skopje, North Macedonia.  
The initial inclusion criteria were: Young women ≥18 
years and ≤35 years, with FSH <10 mIU/mL, AMH ≥3.5 
ng/mL and AFC ≥12 antral follicles on basal ultrasound in-
cluding PCO patients according to The Rotterdam 
ESHRE/ASRM diagnostic criteria (10), own oocytes and 
fresh embryo transfer. To minimize the bias, only the first 
cycle for each patient in that period was analyzed. Patients 
with a history of high response to COH and or history of 
OHSS were also included in the study. All the patients pro-
vided written informed consent before their enrollment in the 
study. Approval for this study was obtained from the 
Institutional Review Board of First Private General Hospital 
Re-Medika, Skopje, North Macedonia (N 03-799/16). The 
final inclusion criteria were: All patients must have ≥14 folli-
cles of over 11mm diameter, (11) and peak estradiol level 
<4,000pg/mL, on trigger day. Randomization was performed 
on the day of triggering, respecting variables that may addi-
tionally influence the final results such as BMI, smoking sta-
tus, age, and sperm analysis. Patients with peak estradiol level 
≥4,000 pg/mL on trigger day, more than 18 oocytes retrieved, 
patients recognized with significant risk for developing 
OHSS, were excluded from the final analysis. A total of 216 
patients, who met the final requirements, entered the study.  
Patients were randomized into one of two groups: Group 
A- Dual trigger group-1,500 IU of hCG at the time of GnRH 
agonist trigger day and Group B-1,500 IU of hCG 35-36 h 
later, on the OPU day. Controlled ovarian stimulation (COS) 
was achieved with short antagonist stimulation protocol used 
in all patients. The initial gonadotropin dose of human 
menopausal gonadotropin (hMG; Menopur; Ferring 
Pharmaceuticals, Parsippany, NJ, the United States) in a total 
dose of 150-225 IU per day, was based on BMI, antral follicle 
count (AFC), AMH, age, and prior response to gonadotropins. 
We used transvaginal ultrasound monitoring for follicular mea-
surement and we also examined the estradiol, progesterone, 
and LH levels. When the leading follicle reached ≥14 mm in 
diameter or serum level of estradiol reached >350 pg/mL, 
GnRH antagonist (Cetrorelix, Cetrotide; Merck Healthcare 
KGAA, Darmstadt, Germany) was started at 0.25 mg subcuta-
neously once per day and continued until the day of oocyte 
maturation trigger. When at least 3 follicles reached ≥17 mm in 
mean diameter group (A) subjects were triggered subcuta-
neously with Triptorelin 0.2 mg (Decapeptile, Ferring GmBh, 
Kiel, Germany) and 1,500 IU of hCG i.m. (Choriomon, IBSA 
Institute Biochemique S.A, Lugano, Switzerland), while group 
(B) subjects were triggered with subcutaneous Triptorelin 0.2 
mg and after 35-36 hours were given 1.500 IU hCG (adminis-
trated at OPU day). Serum LH, levels were assessed the day 
after trigger to ensure adequate LH surge response to the 
GnRH agonist trigger. Transvaginal, ultrasound-guided, 
oocyte retrieval was performed 35-38 h after the trigger. All 
meta-phase II oocytes were injected with a 35 degree angled 
ICSI pipette (Humagen, CooperSurgical, Trumbull, CT, USA). 
Embryo transfer was performed on day 3 (cleavage stage) or 
day 5 (blastocyst stage) after oocyte retrieval, based on embryo 
quality. Evaluation of embryo quality on Day 3 was based on 
blastomeres number, fragmentation rate, multinucleation, and 
early compaction. The selection criteria of Day 3 embryos 
were early cleavage on Day 1, four cells on Day 2, and eight 
cells or early compaction on Day 3, with minimal fragmenta-
tion and no multinucleation. After applying the selection crite-
ria, transfer was only performed using Grade I (excellent qual-
ity) embryos (with at least eight blastomeres on Day 3, of equal 
size, with <10% of fragmentation, and no multinucleation) and 
Grade II (good quality) embryos (6-10 blastomeres, equal or 
moderate in size, with <15-20% of fragmentation, and no mult-
inucleation). Grade III (fair quality) and Grade IV (bad quality) 
embryos were not transferred (12), the minimum conditions re-
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quired for the decision to apply prolonged embryo cultivation 
and blastocyst embryo transfer were: at least  3 embryos that 
were in eight-cell stages or early compaction,  and ≤6 viable 
embryos  Grade I (excellent quality)  or Grade II (good qual-
ity) on Day 3 (13,14). In all patients from the OPU day, the 
luteal phase was supported with the subcutaneous application 
of progesterone, 50mg daily (Prolutex, IBSA Institute 
Biochemique S.A., Lugano, Switzerland) or vaginal proges-
terone gel, 90 mg daily (Crinone 8%; Central Pharma, Bedford, 
United Kingdom) according to market availability of the drugs, 
and E2 tablets, 4-6 mg per day (Estrofem, NovoNordisk, 
Denmark), until a negative pregnancy test or 8 to 10 weeks of 
gestation. After 14 days of embryo transfer, pregnancy tests 
were made with measuring serum level of hCG. Detection of at 
least one gestational sac and embryo with a positive heartbeat 
is considered the confirmation of clinical pregnancy, so we 
made an additional vaginal ultrasound examination after two 
weeks from the positive pregnancy test to make sure of the re-
sults. After embryo transfer, all patients were continuously 
monitored anamnestic, biochemical, and by ultrasound accord-
ing to the ratio of the occurrence of OHSS. The diagnosis and 
classification of OHSS were as mild, moderate, and severe, 
based on the described criteria by Fiedler and  Ezcurra (15) and 
adapted as Mild (abdominal discomfort, nausea/vomiting, diar-
rhea, enlarged ovaries); Moderate (Mild features + Elevated 
hematocrit (>41%), ultrasonographic evidence of ascites, ele-
vated WBC >15,000, hypoproteinemia), Severe (Mild and 
moderate features + hemoconcentration - Hct >55%, clinical 
evidence of ascites WBC >25,000, hydrothorax, oliguria/ 
anuria, Na+ 5 mEq/L, tense ascites, elevated liver enzymes, 
low blood/central venous pressure, rapid weight gain >1 kg in 
24 hours, syncope, severe abdominal pain, venous thrombosis).  
Statistical analysis  
For group comparison were used non-parametric and para-
metric statistical tests (Pearson Chi-square test, Fisher exact 
test, Student t-test for independent samples, Mann-Whitney 
test). 
Significant differences were considered all values of 
p<0.05. 
Results 
A total of 216 patients entered the final analysis of this 
study respecting the inclusion and exclusion criteria. Out of a 
total of 270 patients who passed the basic criteria for admis-
sion to the study and reached the trigger day criteria and ran-
domization, 54 (20%) of the patients underwent the “freeze all 
protocol” due to the above criteria as estradiol higher than 
>4,000 pg/mL, (23/54; 42.59%) on the trigger day as the main 
criterion, more than 18  retrieved oocytes (18/54; 33.33%) in 
the group of estradiol <4,000 pg/mL on trigger day and 13 pa-
tients underwent” freeze all” according to other criteria as they 
had a history of OHSS, very low BMI, and patients recognized 
with significant risk for developing OHSS. Fresh embryo 
transfer was realized in 216 patients and they entered the final 
analysis. Both groups had typical markers for high ovarian re-
serve, which included all patients in the risk group for OHSS. 
The mean AMH in the group (A) was 6.76±3.8 ng/mL vs 
7.56±3.8 ng/mL in Group (B) while the percentage of PCO 
was not significantly higher in the group (A) in comparison to 
the group (B). (Table I) The duration of ovarian stimulation 
and the total dose of gonadotropin required were comparable 
in both groups. (Table II). Even though both of the groups are 
homogenous, regarding several sensitive to OHSS variables: 
age, BMI, AMH, PCOS, and duration of COS (Table I), which 
makes both groups comparable, peak estradiol levels during 
COS and on trigger day were significantly higher in group B 
(2,851.3 vs 2,262.9 pg/mL, p<0.05 ), which indicates a higher 
risk for OHSS and therefore this group contains a slightly 
higher number of patients (triggered with GnRH-agonist) 






Women’s age (y) (mean±SD) 
Man’s age (y) (mean±SD) 
Women smokers (n) (%) 
Man smokers (n) (%) 
Woman’s BMI(kg/m2) mean±SD) 
Previous IVF (n) (%) 
AM hormone (ng/mL) (mean±SD) 
AFC > 12  follicles (n) (%) 
PCO  (n) (%) 
Normospermia Oligospermia 
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Table I: Basal patient characteristics between patients triggered by GnRH agonist + hCG 1500 IU (DUAL TRIGGER), group (A), and 
those triggered by GnRH agonist as a trigger and hCG 1500 IU, 35-36h latter on OPU day, group (B).
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(Table II). There is a significant difference in the percentage 
of oocytes obtained according to the punctured follicles-
“oocyte yield” in dual trigger group (A) (57.79±14.6 % vs 
47.09±17.9%; p<0.005) (Table II). There is no significant dif-
ference between the two (A vs B) groups according to the av-
erage number of retrieved oocytes (13.08 vs 14.41 p=0.08), M 
II oocytes (10.5 vs 10.95 p=0.47 ) and GV (1.24 vs 1.52 
p=0.09). Group (A), even if it had a lower mean number of ob-
tained oocytes and MII oocytes, had a better maturation rate, 
(80.7±15.3 vs 77.4±18.0 p=0.15) and a better percentage of 
patients who had more than 75% of mature oocytes per aspi-
ration (71.43% vs 62.71% p=0.18) (Table III). The dual trig-
ger group (A) had a non-significant but better fertility rate 
(68.46 % vs 64.04 % p=0.07). The number of embryos trans-
ferred was similar in the two groups. The dual trigger group 
had a non-significantly but higher percentage of patients with 
Blastocyst Embryo Transfer (74.49% vs 62.72% p=0.065) 
(Table III). The general occurrence of OHSS was 3.2%. All 
patients had a mild form of OHSS and there were no signifi-
cant differences between the groups in terms of the incidence 
of hyperstimulation syndrome (2.05% vs 4.24%, p=0.37). 
There were no cases of moderate or severe OHSS and no hos-
pitalized patients in both groups (Table III). The dual trigger 
group (A) had a significantly higher ongoing pregnancy rate 
(64.29% vs 45.76% p<0.05) and live birth rate (62.29 % vs 
42.37% p<0.05 ), compared to the GnRH-a trigger group (B).  
Discussion 
An added dose of 1,500 IU hCG applied on the day of as-
piration of the oocytes has already been established in antag-
onist protocol with GnRH as a trigger, in support of the luteal 
phase and successfully elevates serum progesterone levels 
(16,17) especially in the group of patients with serum E2 
<4,000 pg/mL, who have a lower pregnancy rate compared to 
women with peak E2 over 4000 pg/mL, despite intensive 
steroid hormone support (5). 
The use of low doses of hCG at the time of GnRH agonist 
trigger (dual trigger) may be advantageous since it may ensure 
the same correct luteal support as 1,500 IU of hCG 35-36 h 
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(A) Dual Trigger 
n=98 
 




% of oocytes / punctured follicles (mean±SD) 
Oocytes (mean±SD) 
Mature oocytes (mean±SD) 
GV - oocytes (mean±SD) 
Proportion of mature oocytes (%) 
≥75% of mature oocytes (%) 
<75% of mature oocytes (%) 
ICSI - fertilization of oocytes (mean±SD) 
Fertilized oocytes (mean±SD) 
Fertilization rate (%) 
3rd-day transfer 
Blastocyst Embryo Transfer 
Blastocyst transfer (mean±SD) 
Cryo embryos (mean±SD) 
OHSS - mild form (n), (%) 

















































Table II: Controlled ovarian stimulation
Table III: Embryologic outcomes
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later on the OPU day, but also it can be potentially helpful to 
minimize the risk of suboptimal response to GnRH-agonist 
trigger (post-trigger day LH less than 15 IU/l) (18). This fail-
ure can range from empty follicle syndrome (19), lower 
oocyte yield (20) and less retrieved oocytes and mature 
oocytes (21). In our study, we didn’t have patients with empty 
follicle syndrome which is connected with the application of 
contraceptive pills for a longer period and low BMI (20). This 
is not included in our everyday practice for patients undergo-
ing IVF protocols. In every patient, the levels of LH on post-
trigger day were >15 IU/l. The percentage of oocytes obtained 
according to the number of punctured follicles was signifi-
cantly higher in the group (A). (Table III) In the group of Dual 
trigger (A) we obtained not statistically significant lower av-
erage number of oocytes, (13.08 vs 14.41 p=0.08), but what it 
was really interesting that the trend has changed in relation to 
a higher percentage of oocyte maturation and fertilization rate, 
compared to the Dual trigger group. (Table III) The dual trig-
ger group (A) resulted in a significantly higher ongoing preg-
nancy rate and live birth rate (Table IV) 
The main question is “What is the hCG dose on the day of 
application of the GnRH trigger which is powerful enough to 
bring oocyte maturity and luteal support, on one side, and is 
safe in terms of the appearance of OHSS in cycles with the 
fresh transfer?”. To date, there is no consensus on this issue. 
In our study, we compare the same fixed-dose of hCG (1,500 
IU) in the two protocols based on 1) Our observation of dif-
ferent dosage of additional hCG and GnRH agonist trigger day 
in our everyday practice with Dual trigger and we chose the 
most frequent Dual trigger dosage of hCG-1500 IU, 2) Data 
from studies about the safe doses of additional hCG: retro-
grade analysis of 10,427 cycles of IVF-ICIS showed that dual 
trigger from 1,500 IU brings the low risk of OHSS with an in-
cidence of 0.13% of moderate OHSS and a severe OHSS form 
in 0.03% of the population surveyed, which makes these doses 
safe for OHSS occurrence (22). 
A new single-center prospective study demonstrates no sig-
nificant differences in pregnancy rates between the two proto-
cols comparing 1,000 vs 1,500 IU of hCG, with no statistically 
significant higher incidence of OHSS in the group of hCG ap-
plied on OPU day compared to the group of Dual trigger. This 
demonstrates that either protocol may be a reliable option for 
patients at risk of OHSS who desire a fresh transfer (23). 
The main strength of this study is that it is a single study 
center and the compactness of a small team that worked ac-
cording to the same embryological protocol for all patients 
(ICSI), all activities during COS and decisions for type of trig-
ger, “freeze all” as well as follow-up of patients after OPU 
was under the supervision of one senior gynecologist. 
When it comes to OHSS, there were no hospitalized pa-
tients with a moderate or severe form of OHSS. Out of all the 
milder forms of OHSS, there were 5 cases in agonistic trigger 
with 1500 IU hCG and two cases in dual trigger group, which 
gives us the right to say that both protocols are with low risk 
of OHSS occurrence.  
How risky a small additional dose of hCG can be for the 
occurrence of OHSS is shown by one study with a signifi-
cantly high OHSS rate (8,6%) in dual trigger used in hyper re-
sponders in contrast to other studies where the incidence of 
OHSS was below 1% (24). We have to highlight that more of 
the patients, in that study, with a severe form of OHSS, on the 
trigger day had high estradiol >4000 pg/ml and more than 18 
oocytes aspirated, both of them as main indicators, used as a 
criterion, were excluded from our study and replaced with a 
freeze all protocol. On the other hand, even 1500 IU HSC ap-
plied on the day of oocyte aspiration also carries a risk for the 
occurrence of hyperstimulation syndrome (25). This only 
shows that the strict selection of patients is necessary to re-
duce the risk of OHSS. 
An additional benefit in reducing OHSS is a technique 
called segmentation of the protocol: “freeze all” oocytes or 
embryos in the current cycle and their transfer in one of the 
following cycles (26). Anyways, this approach is not possible 
when the patients insist on embryo transfer in the same cycle 
for various reasons, economical, religious, etc. On the other 
hand, a new study shows that even the approach of the GnRH-
agonist trigger alone and the application of the "freeze all" 
technique, does not completely avoid the risk of OHSS (27). 
(A) Dual Trigger 
n=98 




Biochemical Pregnancy (n) (%) 
Clinical pregnancy rate (n) (%) 
Early pregnancy lost (n) (%) 
Ongoing pregnancy rate (n) (%) 
Pregnancy lost after 12 weeks (n) (%) 



















Table IV: Outcome of IVF process
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Conclusion 
Our study showed that 1,500 IU dual trigger gives better 
quality of oocytes and embryos with correct luteal support, the 
same as the second group. We believe that the dual trigger 
protocol takes precedence over luteal support hCG because in 
daily practice it covers certain, although small, percentages of 
the agonist suboptimal endogenic response as a trigger since it 
may ensure retrieval of an appropriate number of mature 
oocytes.  
The adjuvant low dose of hCG (1,500 IU) at the time of 
GnRH agonist trigger day improves clinical pregnancy and 
live birth rates in hyper responders with peak E2 <4,000 
pg/mL without increasing the risk of clinically significant 
OHSS. The protocol of dual trigger and optional freezing all 
oocytes or embryos in patients with a high risk of developing 
OHSS, with peak E2 <4,000 pg/ml or more than 18 oocytes 
aspirated, is a promising technique in everyday practice. 
However, it is still important to timely identify the high-risk 
patients and high-risk situations for developing OHSS. 
 Our study should be further investigated. Prior to the dual 
trigger's routine implementation, further large prospective 
studies are needed to examine the role of dual triggers in the 
high ovarian responders in GnRH-antagonist protocols.  
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